Results 11 to 20 of about 14,398,598 (290)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Journal of Hematology & Oncology, 2023
Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu   +12 more
doaj   +2 more sources

DARPin-fused T cell engager for adenovirus-mediated cancer therapy [PDF]

Molecular Therapy: Oncology
Bispecific T cell engagers are a promising class of therapeutic proteins for cancer therapy. Their potency and small size often come with systemic toxicity and short half-life, making intravenous administration cumbersome.
Patrick C. Freitag, Jonas Kolibius, Ronja Wieboldt, Remi Weber, K. Patricia Hartmann, Merel van Gogh, Dominik Brücher, Heinz Läubli, Andreas Plückthun   +8 more
doaj   +2 more sources

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

Frontiers in Immunology, 2022
Despite the availability of an effective prophylactic vaccine, 820,000 people die annually of hepatitis B virus (HBV)-related liver disease according to WHO.
Bilge Debelec-Butuner, Bilge Debelec-Butuner, Oliver Quitt, Sophia Schreiber, Frank Momburg, Karin Wisskirchen, Karin Wisskirchen, Ulrike Protzer, Ulrike Protzer   +8 more
doaj   +2 more sources

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2⁺ Solid Cancer

Cells, 2023
The efficacy of CD19-specific CAR T cells in the treatment of leukemia/lymphoma relies, at least in part, on the unique properties of the particular CAR and the presence of healthy B cells that enhance the target cell lysis and cytokine secretion through
Andreas A. Hombach, Christine Ambrose, Roy Lobb, Paul Rennert, Hinrich Abken   +4 more
doaj   +2 more sources

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer

Journal of Translational Medicine, 2023
Background Pronectins™ are a new class of fibronectin-3-domain 14th-derived (14Fn3) antibody mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells against cancer.
Caterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, Giada Juli, Craig A. Hokanson, Tatjana Odineca, Stefania Signorelli, Katia Grillone, Serena Ascrizzi, Antonia Mancuso, Nicoletta Staropoli, Basilio Caparello, Maria Cerra, Giuseppe Nisticò, Pierosandro Tagliaferri, Roberto Crea, Daniele Caracciolo, Pierfrancesco Tassone   +17 more
doaj   +2 more sources

Supplementary Data from Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy

, 2022
Supplementary Data from Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager ...
Dan A. Rock (2309449), Kip P. Conner (2054707), Hugo Gonzalez Velozo (15130407), Arja Ray (15130404), Ran You (602464), Jordan Artichoker (15130401), Matthew F. Krummel (15130410)   +6 more
core   +5 more sources

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma

PLoS ONE, 2022
Cholangiocarcinoma (CCA) is a lethal cancer of bile duct epithelial cells with a high mortality rate and limited therapeutic options. An effective treatment is, therefore, urgently needed to improve treatment outcomes for these patients. To develop a new
Thanich Sangsuwannukul, Kamonlapat Supimon, Thaweesak Chieochansin, Kornkan Choomee, Jatuporn Sujjitjoon, Mutita Junking, Pa-thai Yenchitsomanus   +6 more
doaj   +2 more sources

Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy

The Journal of Clinical Investigation
Alyssa M. Duffy, Anshika Goenka, Maryam I. Azeem, Azmain Taz, Sayalee V. Potdar, Sara A. Scott, Ellen Marin, Jonathan L. Kaufman, Craig C. Hofmeister, Nisha S. Joseph, Vikas A. Gupta, Sagar Lonial, Ajay K. Nooka, Madhav V. Dhodapkar, Kavita M. Dhodapkar   +14 more
doaj   +3 more sources

UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma [PDF]

, 2023
UMG1 is a unique epitope of CD43, not expressed by normal cells and tissues of haematopoietic and non-haematopoietic origin, except thymocytes and a minority (<5%) of peripheral blood T lymphocytes.
Grillone, Katia, Belmonte, Beatrice, Tuccillo, Franca Maria, Caracciolo, Daniele, Ascrizzi, Serena, Riillo, Caterina, Polerà, Nicoletta, Juli, Giada, Conforti, Francesco, Gulino, Alessandro, Ballerini, Andrea, Signorelli, Stefania, Cirillo, Maria, Migale, Leonardo, Tagliaferri, Pierosandro, Bonelli, Patrizia, Tassone, Pierfrancesco, Pelizon, Cristina, Di Martino, Maria Teresa, Staropoli, Nicoletta   +19 more
core   +1 more source

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

Frontiers in Immunology, 2023
Bispecific antibodies have attracted more attention in recent years for the treatment of tumors, in which most of them target CD3, which mediates the killing of tumor cells by T cells.
Xinghui Xiao, Xinghui Xiao, Ying Cheng, Ying Cheng, Xiaodong Zheng, Xiaodong Zheng, Yuhang Fang, Yuhang Fang, Yu Zhang, Yu Zhang, Rui Sun, Rui Sun, Zhigang Tian, Zhigang Tian, Zhigang Tian, Haoyu Sun, Haoyu Sun   +16 more
doaj   +1 more source